Bionovo (NASDAQ: BNVI) is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health. The company’s strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo’s first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 07/13/06 | Series A | 1M | Svend Fimland | Unknown |
People
Tom Chesterman (CFO)
Michael Vanderhoof (Board Member)
Mary Tagliaferri (President)
David Naveh (Board Member)
Isaac Cohen (CEO/Chairman)
Competitors
Medigreen Biotechnology Corporation:
Medigreen Biotechnology Corporation, founded on April 10th, 2002, is focusing on the development of botanical new… See Company Profile »